Catalent Inc (NASDAQ:CTLT) shot up 1.3% on Wednesday . The stock traded as high as $25.46 and last traded at $25.39, with a volume of 209,230 shares changing hands. The stock had previously closed at $25.07.

Several research firms have recently weighed in on CTLT. Zacks Investment Research lowered Catalent from a “hold” rating to a “strong sell” rating in a research note on Monday, August 15th. Jefferies Group reiterated a “hold” rating on shares of Catalent in a research note on Thursday, August 4th. TheStreet upgraded Catalent from a “sell” rating to a “hold” rating in a research note on Wednesday, August 17th. Morgan Stanley reiterated a “hold” rating on shares of Catalent in a research note on Tuesday. Finally, Wells Fargo & Co. upgraded Catalent from a “market perform” rating to an “outperform” rating in a research note on Tuesday, June 21st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. Catalent has a consensus rating of “Hold” and a consensus target price of $27.67.

The company has a 50-day moving average of $24.86 and a 200 day moving average of $25.60. The firm has a market cap of $3.15 billion and a price-to-earnings ratio of 15.69.

Catalent (NASDAQ:CTLT) last issued its earnings results on Monday, August 29th. The company reported $0.52 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.53 by $0.01. The company had revenue of $532.20 million for the quarter. During the same period in the prior year, the company posted $0.61 earnings per share. Catalent’s revenue for the quarter was up 4.3% on a year-over-year basis. On average, analysts anticipate that Catalent Inc will post $1.51 earnings per share for the current fiscal year.

In related news, major shareholder Blackstone Management Associat sold 8,785,539 shares of the firm’s stock in a transaction dated Thursday, June 9th. The shares were sold at an average price of $24.51, for a total value of $215,333,560.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Catalent, Inc is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Company’s segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecule’s lifecycle.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.